A translational implication of this model is that RB1/TP53 mutation status—which can be assessed by routine immunohistochemical methods—may serve as surrogate markers for putative tumor progenitors in the population of never smokers with SCLC. This evidence concerns the gene RB1 and small cell lung carcinoma.